Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

233.95CHF
2:26pm BST
Change (% chg)

CHF-1.60 (-0.68%)
Prev Close
CHF235.55
Open
CHF235.05
Day's High
CHF236.35
Day's Low
CHF233.80
Volume
495,693
Avg. Vol
1,508,719
52-wk High
CHF252.85
52-wk Low
CHF206.35

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  ROG.S Industry Sector
P/E (TTM): 22.03 30.89 32.75
EPS (TTM): 11.25 -- --
ROI: 20.46 15.08 14.60
ROE: 46.88 16.60 16.33

BRIEF-Roche Launches Tumor Tissue Analysis Kits For Oncology Research

* ROCHE LAUNCHES NGS AVENIO TUMOR TISSUE ANALYSIS KITS FOR ONCOLOGY RESEARCH

6:08am BST

CORRECTED-UPDATE 1-U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

Oct 10 Celltrion Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.

11 Oct 2018

CORRECTED-U.S. FDA panel backs Celltrion copycat drug of Roche blood cancer drug

Oct 10 An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.

11 Oct 2018

U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

Celltrion Pharm Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.

10 Oct 2018

U.S. FDA panel backs Celltrion copycat drug of Roche blood cancer drug

Oct 10 An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Pharm Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.

10 Oct 2018

BRIEF-Roche Updates Data On Ocrevus To Treat Multiple Sclerosis

* OCREVUS (OCRELIZUMAB) DATA SHOW EARLY INITIATION OF TREATMENT REDUCES DISABILITY PROGRESSION OVER FIVE YEARS IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage:

10 Oct 2018

BRIEF-Roche To Present New Data From Cancer Immunotherapy Programme at ESMO

* ROCHE TO PRESENT NEW POSITIVE DATA FROM ITS BROAD CANCER IMMUNOTHERAPY PROGRAMME

09 Oct 2018

BRIEF-Go Therapeutics Enters Into Agreement With Roche For Glycotargeting Bispecific Cancer Treatment

* GO THERAPEUTICS ENTERS INTO A LICENSE AGREEMENT WITH ROCHE FOR NEW GLYCOTARGETING BISPECIFIC CANCER TREATMENT

02 Oct 2018

BRIEF-Roche Signs Collaboration Agreement To Expand Access To Therapy Information By Integrating Insulin Data From Connected Pens To Its Open Ecosystem

* ROCHE SIGNS COLLABORATION AGREEMENT TO EXPAND ACCESS TO THERAPY INFORMATION BY INTEGRATING INSULIN DATA FROM CONNECTED PENS TO ITS OPEN ECOSYSTEM

01 Oct 2018

BRIEF-Tusk Therapeutics To Be Acquired By Roche

* TUSK THERAPEUTICS - DEAL INCLUDES ADDITIONAL CONTINGENT PAYMENTS OF UP TO EURO 585 MILLION BASED ON MILESTONES

28 Sep 2018

Earnings vs. Estimates